Allogene Therapeutics Q3 2026 Earnings Date & Estimates

Allogene Therapeutics (NASDAQ:ALLO) is a clinical-stage biotechnology company focused on developing “off-the-shelf” allogeneic CAR T-cell therapies for cancer. Unlike autologous CAR T treatments, which are manufactured from an individual patient’s own T cells, Allogene’s products are made from T cells collected from healthy donors and engineered to recognize specific cancer targets. The company uses gene-editing and other technologies intended to support scalable manufacturing and potentially broaden patient access to cell therapy.

Allogene’s pipeline has included investigational treatments for blood cancers and solid tumors. Its lead programs have included cemacabtagene ansemeteucel, also known as cema-cel, an anti-CD19 CAR T-cell therapy being studied in B-cell malignancies, and ALLO-316, an investigational CAR T-cell therapy targeting CD70 in renal cell carcinoma. The company has also advanced programs targeting multiple myeloma and other cancers, with development status subject to change as clinical studies progress.

Founded in 2018, Allogene is headquartered in South San Francisco, California, and conducts research and clinical development activities through studies in the United States and other locations. The company was co-founded and is led by David Chang, who serves as president and chief executive officer. Its therapies remain investigational and are not approved for general commercial use unless specifically authorized by regulators.